Making life better for animals, makes life better. We believe animals enrich our quality of life, so we've made it our purpose to enrich theirs. #WeAreElanco
10 consecutive quarters of growth!📈 Elanco delivered 9% organic CC revenue growth in Q4 and 7% organic CC for the full year, with $892M from innovation in 2025. With this strong momentum, we're raising our 2026 innovation target to $1.15B.
Details:
bit.ly/4aRHZ0o
Growth, innovation, cash. They're our key priorities and we’ve now delivered eight straight quarters of growth. Watch our President and CEO @JeffSimmons2050’s interview with Schwab Network on Q2 earnings and read the full press release here: bit.ly/4opw7IM
.@Elanco Animal Health CEO @JeffSimmons2050 joined @sam_vadas to discuss the company’s latest quarterly report, which sent $ELAN soaring to a new high this year.
Today, $ELAN reported Q2 2025 #Earnings Results, delivering another strong quarter. We saw momentum across all four areas of our business. Overall, 8% organic constant currency growth, led by U.S. Pet Health at 11% growth. Read the press release here: bit.ly/4opw7IM
Today $ELAN reported first quarter 2025 #Earnings Results, outperforming expectations across our key metrics and delivering our seventh consecutive quarter of organic constant currency revenue growth at 4%. Read the full press release: bit.ly/44w8uad
Today, $ELAN reported fourth quarter and full year 2024 #Earnings Results, delivering our sixth consecutive quarter of organic constant currency revenue growth, setting the stage for continued acceleration in 2025.
Read the full press release, bit.ly/4gRgmWh .
Thanks for the spotlight! We're proud to collaborate with the Protein PACT and industry partners to support healthy animals, because making life better for animal makes life better!
Today, we announced the appointment of Dr. Stacey Ma to our Board of Directors. Dr. Ma brings extensive experience in biopharmaceutical development and manufacturing, further strengthening our expertise in these areas. Learn more: bit.ly/4fo5hvF
Cows and #ClimateWeek can co-exist. Earlier this year, we experienced the warmest day in Earth's recorded history. The most efficient opportunity to mitigate warming? Methane. Check out a conversation with our CEO and a leading climate expert to learn more bit.ly/3R4aDBj
@Elanco EVP of innovation and regulatory affairs, Ellen de Brabander discusses the recent divesture of the animal health giant’s aqua business, its high hopes for #Bovaer, and how the newly created One Health Innovation District in Indianapolis will spur the sector’s advances... agtechnavigator.com/Article/…
Today, we announced that Credelio Quattro, our broad-spectrum parasiticide, is moving to the Food and Drug Administration (FDA) final 60-day administrative review phase. U.S. approval is expected in October 2024 and launch expected in Q1 2025.
Read more: bit.ly/3SUgye2
Our President and CEO @JeffSimmons2050 joined @SchwabTV to share his optimism for all that is to come – with not one but three potential blockbuster products coming down the pike. Thanks for having us, @0JRenick - we are excited to lead the future of animal health. #WeAreElanco
Though shares of $ELAN are down 30% from its 52-week highs, @Elanco CEO @JeffSimmons2050 has an optimistic tone as the company is set to launch one new product in each of the next three quarters across two new markets 🐶
Simmons tells @OJRenick what’s coming down the pike:
Though shares of $ELAN are down 30% from its 52-week highs, @Elanco CEO @JeffSimmons2050 has an optimistic tone as the company is set to launch one new product in each of the next three quarters across two new markets 🐶
Simmons tells @OJRenick what’s coming down the pike:
Today, we reported second quarter 2024 financial results, marking our fourth consecutive quarter of underlying revenue growth, and beating guidance in all our key financial metrics.
bit.ly/3LUuFfo
We announced today we have completed the divestiture of our aqua business to Merck Animal Health for approximately $1.3 billion in cash, with approximately $1.05-$1.1 billion in net proceeds available for debt paydown in the third quarter of 2024.
bit.ly/3RVc3Q8